Cost-effectiveness of the MitraClip device in German heart failure patients with secondary mitral regurgitation.

ABSTRACT:

Aim

To evaluate the cost-effectiveness of the MitraClip device (MitraClip) in addition to optimal medical therapy (OMT) in patients with heart failure and secondary mitral regurgitation in Germany.

Methods and results

A model-based economic evaluation was performed to estimate the incremental cost per quality-adjusted life-years (QALYs) for patients with a moderate-to-severe or severe secondary mitral regurgitation receiving MitraClip plus OMT compared with OMT alone from the statutory health insurance (SHI) perspective. Transition probabilities, data on survival rates, and hospitalization rates were obtained from the COAPT trial, a randomized-controlled multicenter trial. Data on health utility and costs were taken from published evidence. To assess parameter uncertainty, s

SUBMITTER: Estler B 

PROVIDER: S-EPMC10060324 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature